Endologix, Inc.  

(Public, NASDAQ:ELGX)   Watch this stock  
Find more results for ELGX
Jul 11 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 11.47 - 18.85
Open     -
Vol / Avg. 0.00/394,915.00
Mkt cap 926.92M
P/E     -
Div/yield     -
EPS -0.03
Shares 64.01M
Beta 1.28
Inst. own 98%
Jul 28, 2014
Q2 2014 Endologix Inc. Earnings Release (Estimated) Add to calendar
Jun 4, 2014
Endologix Inc. at Jefferies Global Healthcare Conference
May 22, 2014
Endologix Inc. Annual Shareholder Meeting
May 15, 2014
Endologix Inc. at Bank of America Merrill Lynch Health Care Conference
May 8, 2014
Endologix Inc. at Deutsche Bank Healthcare Conference - Webcast
Apr 30, 2014
Q1 2014 Endologix Inc. Earnings Conference Call - Webcast
Apr 30, 2014
Q1 2014 Endologix Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 15.92% -12.15%
Operating margin 19.49% -14.27%
EBITD margin - -6.02%
Return on average assets 8.26% -7.63%
Return on average equity 19.69% -16.14%
Employees 482 -
CDP Score - -


IRVINE, CA 92618
United States - Map
+1-949-5957200 (Phone)
+1-949-4579561 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Endologix, Inc. (Endologix) is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company�s principal product is a stent graft and delivery system (ELG System), for the treatment of abdominal aortic aneurysms (AAA) through endovascular repair (EVAR). Its ELG System consists of a self-expanding cobalt chromium alloy stent covered by expanded polytetrafluoroethylene (ePTFE) graft material (ELG Device) and an accompanying delivery catheter. Once its ELG Device is fixed in its proper position within the abdominal aorta, it provides a conduit for blood flow, thereby relieving pressure within the weakened or aneurysmal section of the vessel wall, which reduces the potential for the AAA to rupture. Its ELG System consists of the Company�s ELG Device and catheter delivery system. It also offers proximal aortic extensions and limb extensions, which attach to the main body of its ELG Device.

Officers and directors

John McDermott Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Robert D. Mitchell President
Age: 52
Bio & Compensation  - Reuters
Shelley B. Thunen Chief Financial Officer and Corporate Secretary
Age: 61
Bio & Compensation  - Reuters
Todd G. Abraham Vice President - Operations
Age: 50
Bio & Compensation  - Reuters
Joseph A. DeJohn Vice President - Sales
Age: 53
Bio & Compensation  - Reuters
David M. Jennings Vice President - Human Resources
Age: 59
Bio & Compensation  - Reuters
Jose A. Lima Vice President - Quality
Age: 48
Bio & Compensation  - Reuters
Charles Love Vice President - Clinical Affairs
Age: 52
Bio & Compensation  - Reuters
James E. Machek Vice President - Research and Development
Age: 56
Bio & Compensation  - Reuters
Janet Fauls Director - Regulatory Affairs
Age: 51
Bio & Compensation  - Reuters